Advanced Filters
noise

Seol, Korea, Republic of Clinical Trials

A listing of Seol, Korea, Republic of clinical trials actively recruiting patients volunteers.

Found 1,476 clinical trials
D Dong Woo Han

EEG and ANI Guided Anesthesia and Quality of Recovery

This study aims to assess whether electroencephalogram (EEG) and nociception level-guided anesthesia can improve quality of recovery after laparoscopic gynecological surgery compared with standard care. Patients will be randomly assigned to either EEG and Analgesia Nociception Index (ANI)-guided anesthesia group (EEG-and-ANI-Guided group) or usual care group (control group). Primary outcome …

19 years of age Female Phase N/A
S Su-Jin Kim, M.D., Ph.D.

The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma

Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumors originating from catecholamine producing chromaffin cells in the adrenal medulla and extra-adrenal paraganglia. The overall age-standardized incidence rate is 0.18 per 100,000 person-years in Korea. The definitive treatment of PPGL is surgical excision of tumor. However, surgery is associated with a high …

19 - 70 years of age All Phase 4
S Sung Hwan Kim, MD

Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis

This study is evaluating the effects of riding on a cycle ergometer while experiencing virtual reality to determine its effect on mood.

19 - 79 years of age All Phase 2
H Han Gil Seo, MD, PhD

Comprehensive Swallowing Rehabilitation in Patients With MSA

The purpose of this study is to investigate the effect of comprehensive swallowing rehabilitation in patients with multiple system atrophy.

19 years of age All Phase N/A
I In-Jung Jun

Effect of Remimazolam and Propofol on Postoperative Delirium

Remimazolam is an ultra-short acting benzodiazepine agonist which is used widely for general anesthesia and sedation. Remimazolam has several advantages. Remimazolam is rapidly metabolized by tissue esterase that it does not accumulate even after infusion for long periods of time. The presence of reversal agents (flumazenil) is also advantageous. Also, …

65 - 100 years of age All Phase N/A
S Seung Soon Lee, MD

Efficacy and Safety of FMT for the Decolonization of MDROs in the Intestinal Tract

The goal of this unblinded randomized controlled trial is to evaluate the efficacy and safety of fecal microbiota transplantation for the decolonization of carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CP-CRE) or vancomycin-resistant Enterococci (VRE) in the intestinal tract. The study is planned to be conducted to test the superiority hypothesis that the decolonization …

20 years of age All Phase N/A
S Sehhoon Park

Developing Artificial Intelligence-based Algorism to Predict Side Effects and Symptoms From Chemotherapy

In this study, the investigators obtain wearable disease based biomarkers from patients diagnosed with cancer and undergoing chemotherapy, and simultaneously measure patient self-reported adverse events through an app to evaluate chemotherapy completion rates, emergency room visits, and frequency of CTCAE adverse events. The investigators will develop an artificial intelligence-based algorism …

20 years of age All Phase N/A
Y YoungKoo Lee, MD. Ph D.

A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial

This is a follow-up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial (ALLO-ASC-DFU-302) for 24 months

19 - 75 years of age All Phase N/A
B Byoung Chul Cho

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Combination treatment of Durvalumab with chemoradiotherapy is ongoing for head/neck cancer, renal cell carcinoma, melanoma, and non-small cell lung cancer (NCT02318771) and pancreatic cancer (NCT02305186).Combining Durvalumab with neoadjuvant chemoradiotherapy is a promising strategy to improve clinical outcome in stage III lung cancer. Using serial biopsied and surgically resected fresh tissue …

20 years of age All Phase 1/2

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

The objective of this bridging study is to acquire new drug approval in Korea for camrelizumab (SHR-1210), a drug that has already been approved in China for treatment in patients with histologically or cytologically confirmed advanced or metastatic (Stage IIIB-IV), EGFR/ALK wild-type, non-squamous, non-small cell lung cancer. In this study, …

19 - 80 years of age All Phase 2

Simplify language using AI